Studies are designed to evaluate the potential for the compound to interact with DNA and cause genetic mutations, a critical measure of safety required for IND submission CAMBRIDGE, Mass. -…
Read More
Analysis showed no photoreactive potential for EB-003, further derisking its continued development for the treatment of neuropsychiatric disorders including depression, anxiety and PTSD. Phototoxicity testing is a part of preclinical…
Read More
Product Development Highlights: Continued advancement of lead candidate EB-003 with IND-enabling studies progressing toward planned first-in-human clinical trial Reported additional preclinical data for EB-003 demonstrating dual Gq and β-arrestin signaling…
Read More
Claims to methods for treating a psychiatric disorder using novel pharmaceutical drug formulations encompass an EVM301 Series of drug candidates of carboxylated psilocybin derivatives, targeting various difficult-to-treat mental health disorders…
Read More
Previously reported results support continued development of EB-003 for PTSD and other neuropsychiatric conditions Recent U.S. Executive Order supporting psychedelic-inspired therapies highlights growing focus on PTSD and reinforces opportunity for…
Read More
CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that Director and…
Read More
$5 million upfront with up to approximately $8.9 million of potential aggregate proceeds upon the exercise in full of warrants CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or…
Read More
$5 million upfront with up to approximately $8.9 million of potential aggregate proceeds upon the exercise in full of warrants CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or…
Read More
Patent provides added depth to Enveric's EVM301 intellectual property portfolio of potential neuroplastogenic molecules for non-hallucinogenic treatment of neuropsychiatric conditions CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the…
Read More
Product Development Highlights: Reported positive preclinical results for lead drug candidate EB-003, showing statistically significant improvements in animal models of severe chronic depression and despair and in post-traumatic stress disorder…
Read More
